Nahdi Medical Company (4164.SR)
SAR 114.2
(-0.17%)
SAR 114.2
(-0.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.64 Billion SAR | -0.42% |
| 2022 | 1.61 Billion SAR | 9.63% |
| 2021 | 1.5 Billion SAR | -1.27% |
| 2020 | 1.47 Billion SAR | 12.94% |
| 2019 | 1.31 Billion SAR | 61.39% |
| 2018 | 788.64 Million SAR | -9.45% |
| 2017 | 899.53 Million SAR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 393.61 Million SAR | 16.68% |
| 2024 Q3 | 175.8 Million SAR | -21.34% |
| 2024 Q2 | 462.95 Million SAR | 7.93% |
| 2023 Q4 | 315.22 Million SAR | -20.42% |
| 2023 FY | - SAR | -0.42% |
| 2023 Q3 | 396.1 Million SAR | -11.03% |
| 2023 Q2 | 445.19 Million SAR | 2.12% |
| 2023 Q1 | 435.94 Million SAR | 46.03% |
| 2022 Q2 | 451.68 Million SAR | 10.15% |
| 2022 Q1 | 410.06 Million SAR | 48.94% |
| 2022 Q3 | 438.89 Million SAR | -2.83% |
| 2022 FY | - SAR | 9.63% |
| 2022 Q4 | 298.52 Million SAR | -31.98% |
| 2021 FY | - SAR | -1.27% |
| 2021 Q4 | 275.32 Million SAR | -33.64% |
| 2021 Q3 | 414.93 Million SAR | 2.48% |
| 2021 Q2 | 404.9 Million SAR | 11.39% |
| 2021 Q1 | 363.49 Million SAR | 52.95% |
| 2020 Q1 | 358.3 Million SAR | 0.0% |
| 2020 FY | - SAR | 12.94% |
| 2020 Q4 | 237.65 Million SAR | 52.69% |
| 2020 Q3 | 155.64 Million SAR | -55.02% |
| 2020 Q2 | 346.03 Million SAR | -3.42% |
| 2019 FY | - SAR | 61.39% |
| 2018 FY | - SAR | -9.45% |
| 2017 FY | - SAR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Middle East Pharmaceutical Industries Co. | 85.13 Million SAR | -1830.595% |
| Al-Dawaa Medical Services Company | 830.43 Million SAR | -97.926% |
| Al-Razi Medical Co. | 5.64 Million SAR | -28991.391% |
| Almujtama Alraida Medical Co. | 19.53 Million SAR | -8314.763% |